Pacira Pharmaceuticals Company Profile (NASDAQ:PCRX)

About Pacira Pharmaceuticals

Pacira Pharmaceuticals logoPacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product candidate, EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine encapsulated in DepoFoam, and is an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PCRX
  • CUSIP: 69512710
Key Metrics:
  • Previous Close: $40.21
  • 50 Day Moving Average: $39.78
  • 200 Day Moving Average: $47.66
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 50.90
  • P/E Growth: 1.32
  • Market Cap: $1.50B
  • Outstanding Shares: 37,278,000
  • Beta: 1.59
Additional Links:
Companies Related to Pacira Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Pacira Pharmaceuticals (NASDAQ:PCRX) (?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $75.80 (88.51% upside)

Analysts' Ratings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Show:
DateFirmActionRatingPrice TargetDetails
8/5/2016BMO Capital MarketsReiterated RatingSell$36.00View Rating Details
8/5/2016Brean CapitalReiterated RatingHoldView Rating Details
8/4/2016WedbushReiterated RatingOutperform$109.00 -> $105.00View Rating Details
8/3/2016Piper Jaffray Cos.Reiterated RatingOverweight$81.00View Rating Details
8/2/2016MizuhoReiterated RatingBuy$64.00View Rating Details
4/20/2016Canaccord GenuityReiterated RatingBuyView Rating Details
2/28/2016NomuraReiterated RatingBuy$100.00View Rating Details
1/29/2016Bank of America Corp.UpgradeNeutral -> Buy$75.00View Rating Details
1/9/2016Leerink SwannReiterated RatingHoldView Rating Details
1/6/2016JMP SecuritiesReiterated RatingMkt Outperform$92.00View Rating Details
9/24/2015Barclays PLCReiterated RatingBuyView Rating Details
7/27/2015Jefferies GroupReiterated RatingBuy$81.00 -> $72.00View Rating Details
1/30/2015Goldman Sachs Group Inc.Boost Price Target$126.00View Rating Details
(Data available from 8/27/2014 forward)

Earnings

Earnings History for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2016        
8/4/2016Q216$0.03$0.19$67.80 million$69.60 millionViewListenView Earnings Details
5/2/2016Q116$0.07$0.15$67.11 million$65.50 millionViewListenView Earnings Details
2/25/2016Q415$0.27$0.20$68.40 million$69.30 millionViewListenView Earnings Details
10/27/2015Q315$0.15$0.10$60.44 million$62.20 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.20$62.97 million$59.10 millionViewListenView Earnings Details
4/30/2015Q115$0.02$0.05$61.11 million$58.30 millionViewListenView Earnings Details
2/24/2015Q4$0.27$0.35$61.62 million$61.80 millionViewListenView Earnings Details
10/30/2014Q314$0.10$0.14$52.20 million$52.00 millionViewListenView Earnings Details
7/31/2014Q214($0.21)$0.04$42.20 million$47.20 millionViewListenView Earnings Details
5/1/2014Q1($0.32)($0.19)$35.40 million$36.70 millionViewListenView Earnings Details
2/25/2014Q4($0.31)($0.33)ViewListenView Earnings Details
10/31/2013Q313($0.35)($0.30)$22.10 million$23.30 millionViewListenView Earnings Details
11/1/2012Q312($0.44)($0.49)$7.85 million$8.50 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pacira Pharmaceuticals (NASDAQ:PCRX)
Current Year EPS Consensus Estimate: $0.23 EPS
Next Year EPS Consensus Estimate: $0.79 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.20)($0.20)($0.20)
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Pacira Pharmaceuticals (NASDAQ:PCRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pacira Pharmaceuticals (NASDAQ:PCRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016David M. StackCEOSell15,000$45.32$679,800.00View SEC Filing  
8/15/2016James S. ScibettaPresidentSell25,000$45.21$1,130,250.00View SEC Filing  
6/7/2016Lauren Bullaro RikerVPSell938$47.66$44,705.08View SEC Filing  
6/6/2016Kristen Marie WilliamsCAOSell600$47.20$28,320.00View SEC Filing  
6/6/2016Lauren Bullaro RikerVPSell321$47.20$15,151.20View SEC Filing  
6/6/2016Mark A KronenfeldDirectorSell900$46.95$42,255.00View SEC Filing  
4/15/2016David M StackCEOSell25,000$64.14$1,603,500.00View SEC Filing  
1/29/2016Scott BraunsteinSVPBuy2,000$58.92$117,840.00View SEC Filing  
1/27/2016James B JonesSVPBuy500$62.50$31,250.00View SEC Filing  
1/15/2016David M. StackCEOSell15,000$63.84$957,600.00View SEC Filing  
1/12/2016James B JonesSVPBuy1,000$66.00$66,000.00View SEC Filing  
1/12/2016John P Phd LongeneckerDirectorBuy300$66.55$19,965.00View SEC Filing  
10/15/2015David M. StackCEOSell15,000$37.57$563,550.00View SEC Filing  
9/11/2015James S ScibettaCFOBuy5,000$61.37$306,850.00View SEC Filing  
8/17/2015Paul J HastingsDirectorSell3,000$60.02$180,060.00View SEC Filing  
7/15/2015David M StackCEOSell15,000$67.78$1,016,700.00View SEC Filing  
4/15/2015David M StackCEOSell25,000$90.50$2,262,500.00View SEC Filing  
4/10/2015Paul J HastingsDirectorSell2,500$88.00$220,000.00View SEC Filing  
3/16/2015Lauren Bullaro RikerDirectorSell5,000$95.34$476,700.00View SEC Filing  
3/13/2015Gary W PaceDirectorBuy1,000$93.83$93,830.00View SEC Filing  
2/6/2015James S ScibettaCFOSell15,000$111.22$1,668,300.00View SEC Filing  
1/15/2015David M StackCEOSell15,000$97.52$1,462,800.00View SEC Filing  
1/12/2015Paul J HastingsDirectorSell2,500$94.06$235,150.00View SEC Filing  
12/29/2014John P Phd LongeneckerDirectorSell1,000$93.32$93,320.00View SEC Filing  
12/5/2014Dennis L WingerDirectorBuy2,645$94.54$250,058.30View SEC Filing  
11/7/2014James S ScibettaCFOSell15,000$87.18$1,307,700.00View SEC Filing  
11/7/2014Taunia MarkvickaSVPBuy230$86.62$19,922.60View SEC Filing  
10/10/2014Paul J HastingsDirectorSell2,500$94.87$237,175.00View SEC Filing  
9/29/2014John P Phd LongeneckerDirectorSell1,000$96.40$96,400.00View SEC Filing  
8/29/2014Andreas WickiDirectorSell21,494$108.11$2,323,716.34View SEC Filing  
8/27/2014Andreas WickiDirectorSell55,813$108.08$6,032,269.04View SEC Filing  
8/26/2014Andreas WickiDirectorSell24,207$108.11$2,617,018.77View SEC Filing  
8/25/2014Andreas WickiDirectorSell30,000$108.07$3,242,100.00View SEC Filing  
8/11/2014Andreas WickiDirectorSell150,000$101.25$15,187,500.00View SEC Filing  
8/8/2014James S ScibettaCFOSell15,000$99.63$1,494,450.00View SEC Filing  
8/7/2014Gary PatouInsiderSell20,000$100.26$2,005,200.00View SEC Filing  
7/15/2014David M StackCEOSell15,000$86.75$1,301,250.00View SEC Filing  
7/14/2014Gary PatouInsiderSell29,700$86.96$2,582,712.00View SEC Filing  
7/10/2014Paul J HastingsDirectorSell2,500$84.41$211,025.00View SEC Filing  
6/6/2014Andreas WickiDirectorSell67,900$82.62$5,609,898.00View SEC Filing  
6/3/2014Andreas WickiDirectorSell68,000$80.69$5,486,920.00View SEC Filing  
5/27/2014Andreas WickiDirectorSell64,400$77.93$5,018,692.00View SEC Filing  
5/21/2014Andreas WickiDirectorSell3,600$77.80$280,080.00View SEC Filing  
5/12/2014Gary PatouInsiderSell30,000$74.39$2,231,700.00View SEC Filing  
5/9/2014David StackCEOSell25,000$73.94$1,848,500.00View SEC Filing  
5/9/2014Laura BregeDirectorSell10,000$73.85$738,500.00View SEC Filing  
5/8/2014Andreas WickiDirectorSell23,220$75.76$1,759,147.20View SEC Filing  
5/8/2014James ScibettaCFOSell15,000$75.05$1,125,750.00View SEC Filing  
5/7/2014Andreas WickiDirectorSell44,780$75.78$3,393,428.40View SEC Filing  
3/28/2014John Phd LongeneckerDirectorSell1,000$64.63$64,630.00View SEC Filing  
3/6/2014Andreas WickiDirectorSell24,887$80.16$1,994,941.92View SEC Filing  
12/30/2013David StackCEOSell15,000$55.84$837,600.00View SEC Filing  
12/30/2013James ScibettaCFOSell10,000$55.55$555,500.00View SEC Filing  
12/30/2013John Phd LongeneckerDirectorSell2,500$55.55$138,875.00View SEC Filing  
10/1/2013Gary PatouInsiderSell20,000$48.92$978,400.00View SEC Filing  
9/11/2013Andreas WickiDirectorSell17,783$37.25$662,416.75View SEC Filing  
8/14/2013Taunia MarkvickaVPSell14,700$37.00$543,900.00View SEC Filing  
7/22/2013Andreas WickiDirectorSell75,958$35.06$2,663,087.48View SEC Filing  
7/18/2013Andreas WickiDirectorSell25,560$33.45$854,982.00View SEC Filing  
7/16/2013Andreas WickiDirectorSell48,482$33.28$1,613,480.96View SEC Filing  
7/12/2013Taunia MarkvickaVPSell29,754$32.00$952,128.00View SEC Filing  
7/11/2013Andreas WickiDirectorSell80,000$31.48$2,518,400.00View SEC Filing  
7/5/2013Andreas WickiDirectorSell44,021$30.80$1,355,846.80View SEC Filing  
7/3/2013Andreas WickiDirectorSell114,448$30.21$3,457,474.08View SEC Filing  
7/2/2013Gary PatouInsiderSell40,000$29.44$1,177,600.00View SEC Filing  
6/28/2013David M StackCEOSell15,000$28.73$430,950.00View SEC Filing  
6/28/2013James S ScibettaCFOSell10,000$28.05$280,500.00View SEC Filing  
6/28/2013John P Phd LongeneckerDirectorSell2,000$28.09$56,180.00View SEC Filing  
6/24/2013Fred A MiddletonDirectorSell75,900$29.13$2,210,967.00View SEC Filing  
6/20/2013Fred A MiddletonDirectorSell144,100$29.32$4,225,012.00View SEC Filing  
6/19/2013Andreas WickiDirectorSell35,407$29.90$1,058,669.30View SEC Filing  
6/17/2013Andreas WickiDirectorSell50,145$29.86$1,497,329.70View SEC Filing  
6/13/2013John PrattInsiderSell21,032$30.00$630,960.00View SEC Filing  
6/13/2013Luke EvninDirectorSell22,746$30.07$683,972.22View SEC Filing  
6/12/2013Andreas WickiDirectorSell4,409$30.00$132,270.00View SEC Filing  
6/11/2013Andreas WickiDirectorSell11,500$30.00$345,000.00View SEC Filing  
6/11/2013John PrattInsiderSell18,343$30.00$550,290.00View SEC Filing  
6/5/2013Andreas WickiDirectorSell15,500$30.26$469,030.00View SEC Filing  
6/3/2013Andreas WickiDirectorSell1,900$30.00$57,000.00View SEC Filing  
5/31/2013Luke EvninDirectorSell54,517$30.00$1,635,510.00View SEC Filing  
5/29/2013Luke EvninDirectorSell215,528$30.86$6,651,194.08View SEC Filing  
5/22/2013Andreas WickiDirectorSell18,471$30.00$554,130.00View SEC Filing  
5/20/2013Andreas WickiDirectorSell14,374$30.00$431,220.00View SEC Filing  
3/25/2013Andreas WickiDirectorSell290,900$27.95$8,130,655.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pacira Pharmaceuticals (NASDAQ:PCRX)
DateHeadline
investornewswire.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - August 24 at 6:30 PM
investornewswire.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Reports Sales Of $69.64, Surprising Estimates By 3.074% - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - August 23 at 11:11 AM
investornewswire.com logoWill Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Hit $109 Price Target? - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - August 18 at 6:55 PM
fortune.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX): Updated Analyst Ratings - Review Fortune (NASDAQ:PCRX)
reviewfortune.com - August 8 at 11:27 AM
News IconPacira Pharmaceuticals Inc. (NASDAQ:PCRX) reported a second-quarter loss (NASDAQ:PCRX)
myhealthbowl.com - August 7 at 10:50 AM
equities.com logoPacira Pharmaceuticals Inc. (PCRX) Jumps 19.05% on August 04 - Equities.com (NASDAQ:PCRX)
www.equities.com - August 5 at 6:59 PM
News IconTeekay Corporation (NYSE:TK) & Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Trend Analysis Report - Money News (press release) (NASDAQ:PCRX)
www.newsismoney.com - August 5 at 6:59 PM
feeds.benzinga.com logoMajor Averages Close Thursday's Session Mostly Unchanged (NASDAQ:PCRX)
feeds.benzinga.com - August 4 at 5:55 PM
fool.com logoWhy Pacira Pharmaceuticals, Inc. Shares Are Spiking 21% Today (NASDAQ:PCRX)
www.fool.com - August 4 at 1:13 PM
equities.com logoPacira Pharmaceuticals Inc. (PCRX) is Trading Higher on Unusual Volume for August 01 - Equities.com (NASDAQ:PCRX)
www.equities.com - August 3 at 10:00 AM
investornewswire.com logoCan Shares Of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Hit $105? - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - July 28 at 7:01 PM
News IconThe Statistics Don't Lie: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Earnings Preview - The Voice Registrar (NASDAQ:PCRX)
voiceregistrar.com - July 22 at 6:36 PM
investornewswire.com logoIs $105 Price Target Attainable For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)? - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - July 21 at 7:05 PM
streetupdates.com logoAnalysts Reviewing Stocks: CVS Health Corporation (NYSE:CVS) , Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Street Updates (NASDAQ:PCRX)
www.streetupdates.com - July 21 at 7:05 PM
equities.com logoPacira Pharmaceuticals Inc. (PCRX) Jumps 7.96% on July 20 - Equities.com (NASDAQ:PCRX)
www.equities.com - July 21 at 7:05 PM
news.cmlviz.com logoPacira Pharmaceuticals Inc (NASDAQ:PCRX) Realized Volatility Hits A Notable High - CML News (NASDAQ:PCRX)
news.cmlviz.com - July 21 at 7:05 PM
investornewswire.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Expected To Post Sales Of $1127.9 - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - July 19 at 7:09 AM
News IconShares Experiencing a Downtrend: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - TGP (NASDAQ:PCRX)
telanaganapress.com - July 17 at 10:57 AM
equities.com logoPacira Pharmaceuticals Inc. (PCRX) Drops 5.87% on July 13 - Equities.com (NASDAQ:PCRX)
www.equities.com - July 15 at 11:49 AM
publicnow.com logoPacira Pharmaceuticals Announces Timing for Second Quarter 2016 Financial Results Webcast and Conference Call (NASDAQ:PCRX)
www.publicnow.com - July 15 at 7:58 AM
investornewswire.com logoStrong Sell Calls For Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) At 0 - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - July 14 at 10:22 AM
News IconIs Pacira Pharmaceuticals Inc a Sell? The Stock Declines Again - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - July 13 at 7:07 PM
News IconTrading Performance and Target Watch for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - July 12 at 11:06 AM
News IconPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:PCRX)
www.engelwooddaily.com - July 11 at 6:44 PM
investornewswire.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Yearly Sales Target At $1127.9 - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - July 11 at 6:44 PM
News IconStock Performance Rundown on: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - July 11 at 6:44 PM
fiscalstandard.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:PCRX)
www.fiscalstandard.com - July 11 at 6:44 PM
News IconNext Century Growth Investors LLC Increased Pacira Pharmaceuticals (NASDAQ:PCRX) by $14.12 Million as Shares ... - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - July 8 at 6:46 PM
equities.com logoPacira Pharmaceuticals Inc. (PCRX) Jumps 5.14% on July 06 - Equities.com (NASDAQ:PCRX)
www.equities.com - July 8 at 6:46 PM
investornewswire.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Expected to Reach Highs Of $105 - Investor Newswire (NASDAQ:PCRX)
www.investornewswire.com - July 6 at 6:56 PM
News IconStock Rating Watch and Earnings Insight for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - July 6 at 11:22 AM
News IconShare Volatility in Focus: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Engelwood Daily (NASDAQ:PCRX)
www.engelwooddaily.com - July 5 at 6:30 PM
News IconHC Stocks to watch for: Pacira Pharmaceuticals Inc (NASDAQ:PCRX), Sarepta Therapeutics Inc (NASDAQ:SRPT) - share market updates (press release) (NASDAQ:PCRX)
sharemarketupdates.com - July 5 at 11:14 AM
News IconShare Performance Recap for: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - July 3 at 6:07 PM
equities.com logoPacira Pharmaceuticals Inc. (PCRX) Drops 11.26% on June 30 - Equities.com (NASDAQ:PCRX)
www.equities.com - July 2 at 6:24 PM
benzinga.com logoExparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines (NASDAQ:PCRX)
www.benzinga.com - July 2 at 9:30 AM
News IconTracking Stock Volatility for: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Engelwood Daily (NASDAQ:PCRX)
www.engelwooddaily.com - July 1 at 6:45 PM
biz.yahoo.com logoPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclo (NASDAQ:PCRX)
biz.yahoo.com - July 1 at 7:37 AM
schaeffersresearch.com logoAnalyst Update: Pacira Pharmaceuticals Inc, McKesson Corporation, and Newfield Exploration Co. (NASDAQ:PCRX)
www.schaeffersresearch.com - June 29 at 6:39 PM
feeds.benzinga.com logoPacira Shares Tumble Following BMO's New Underperform Rating (NASDAQ:PCRX)
feeds.benzinga.com - June 29 at 5:11 PM
live-pr.com logoNew Market Report: Pacira Pharmaceuticals, Inc. (PCRX) - Financial and Strategic SWOT Analysis Review (NASDAQ:PCRX)
www.live-pr.com - June 27 at 6:45 PM
seekingalpha.com logoMany Growth Catalysts For Pacira - Seeking Alpha (NASDAQ:PCRX)
seekingalpha.com - June 26 at 5:53 PM
News IconStock Performance Focus on: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Press Telegraph (NASDAQ:PCRX)
presstelegraph.com - June 26 at 5:53 PM
247wallst.com logoA Biotech and a Medical Device Stock, Each With Massive Upside Potential (NASDAQ:PCRX)
247wallst.com - June 23 at 10:55 AM
fiscalstandard.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Analyst Price Targets For The Coming Week - Fiscal Standard (NASDAQ:PCRX)
www.fiscalstandard.com - June 20 at 8:21 AM
biz.yahoo.com logoPACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to (NASDAQ:PCRX)
biz.yahoo.com - June 17 at 4:13 PM
News IconPerformance watch list: Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - News Oracle (NASDAQ:PCRX)
www.newsoracle.com - June 16 at 6:59 PM
News IconEarnings Review: Ceres, Inc. (NASDAQ:CERE), Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) - Beacon Chronicle (NASDAQ:PCRX)
www.beaconchronicle.com - June 16 at 6:59 PM
nasdaq.com logoRelative Strength Alert For Pacira Pharmaceuticals (NASDAQ:PCRX)
www.nasdaq.com - June 15 at 6:42 PM
news.cmlviz.com logoPacira Pharmaceuticals, Inc. (NASDAQ:PCRX) Fundamental Star Rating Report - CML News (NASDAQ:PCRX)
news.cmlviz.com - June 9 at 7:06 PM

Social

Pacira Pharmaceuticals (NASDAQ:PCRX) Chart for Saturday, August, 27, 2016


Last Updated on 8/27/2016 by MarketBeat.com Staff